Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2022 - 09 - 15 symbols : SNYNF save search
Positive Dupixent® (dupilumab) Phase 3 Data in Children Aged 6 Months to 5 Years with Moderate-to-severe Atopic Dermatitis Published in The Lancet
Published: 2022-09-15 (Crawled : 23:00) - prnewswire.com
SNYNF | News | $92.7 600K
|
Health Technology
|
| O: 0.74%
H: 0.91%
C: -0.74%
SNY | News | $46.34 2.09% 620K
|
Health Technology
|
| O: -0.52%
H: 0.0%
C: 0.0%
REGN | $894.35 0.04% 140K
|
Health Technology
|
| O: 0.62%
H: 1.12%
C: 0.01%
dupixent children lancet dermatitis positive
New Jersey To Celebrate Year of Women in Manufacturing at 10th Annual 'MADE in New Jersey' Manufacturing Day
Published: 2022-09-15 (Crawled : 23:00) - prnewswire.com
SNYNF | News | $92.7 600K
|
Health Technology
|
| O: 0.74%
H: 0.91%
C: -0.74%
SNY | News | $46.34 2.09% 620K
|
Health Technology
|
| O: -0.52%
H: 0.0%
C: 0.0%
day women year
Worldwide Irritable Bowel Syndrome with Constipation Drugs Industry to 2030 - by Drug Type, Prescription Type and Region
Published: 2022-09-15 (Crawled : 18:00) - prnewswire.com
SNYNF | News | $92.7 600K
|
Health Technology
|
| O: 1.6%
H: 0.0%
C: -6.5%
AZNCF | $138.24 800
|
Health Technology
|
| O: 0.97%
H: 0.0%
C: -3.99%
ALPMY | $9.47 520K
|
Manufacturing
|
| O: 0.22%
H: 0.14%
C: -0.43%
ABT | News | $107.24 1.87% 2M
|
Health Technology
|
| O: 0.26%
H: 0.96%
C: -0.94%
SNY | News | $46.34 2.09% 620K
|
Health Technology
|
| O: 0.4%
H: 0.84%
C: 0.37%
IRWD | $7.785 2.43% 320K
|
Health Technology
|
| O: 0.0%
H: 0.72%
C: -1.27%
AZN | $68.545 0.27% 1.2M
|
Health Technology
|
| O: -0.19%
H: 0.09%
C: -0.8%
ARDX | News | $6.445 0.08% 890K
|
Health Technology
|
| O: -2.9%
H: 3.73%
C: 2.24%
drug
BioNJ Releases Speakers and Agenda for 2022 C-Suite Summit
Published: 2022-09-15 (Crawled : 17:00) - prnewswire.com
SNYNF | News | $92.7 600K
|
Health Technology
|
| O: 1.6%
H: 0.0%
C: -6.5%
SNY | News | $46.34 2.09% 620K
|
Health Technology
|
| O: 0.4%
H: 0.84%
C: 0.37%
YOOBIC Celebrates Banner Year in North America With Accelerating Global Growth
Published: 2022-09-15 (Crawled : 14:00) - prnewswire.com
SNYNF | News | $92.7 600K
|
Health Technology
|
| O: 1.6%
H: 0.0%
C: -6.5%
SNY | News | $46.34 2.09% 620K
|
Health Technology
|
| O: 0.4%
H: 0.84%
C: 0.37%
america global year growth
Experimental Test Promises to Predict Side-Effects and Cancer's Return in Patients Treated with Immunotherapy
Published: 2022-09-15 (Crawled : 14:00) - prnewswire.com
SNYNF | News | $92.7 600K
|
Health Technology
|
| O: 1.6%
H: 0.0%
C: -6.5%
SNY | News | $46.34 2.09% 620K
|
Health Technology
|
| O: 0.4%
H: 0.84%
C: 0.37%
immunotherapy test cancer
Caladrius Biosciences and Cend Therapeutics Announce Closing of Merger and the Emergence of Lisata Therapeutics
Published: 2022-09-15 (Crawled : 13:20) - globenewswire.com
SNYNF | News | $92.7 600K
|
Health Technology
|
| O: 1.6%
H: 0.0%
C: -6.5%
SNY | News | $46.34 2.09% 620K
|
Health Technology
|
| O: 0.4%
H: 0.84%
C: 0.37%
therapeutics
Regeneron and Alnylam Report Promising Data from Ongoing Phase 1 Study of ALN-HSD in NASH Patients and Healthy Volunteers
Published: 2022-09-15 (Crawled : 13:00) - biospace.com/
SNYNF | News | $92.7 600K
|
Health Technology
|
| O: 1.6%
H: 0.0%
C: -6.5%
SNY | News | $46.34 2.09% 620K
|
Health Technology
|
| O: 0.4%
H: 0.84%
C: 0.37%
REGN | $894.35 0.04% 140K
|
Health Technology
|
| O: -0.41%
H: 3.27%
C: 1.6%
ALNY | News | $146.34 0.81% 64K
|
Health Technology
|
| O: -0.9%
H: 2.16%
C: 1.01%
ongoing report nash study phase 1
Alnylam and Regeneron Report Promising Data from Ongoing Phase 1 Study of ALN-HSD in NASH Patients and Healthy Volunteers
Published: 2022-09-15 (Crawled : 12:00) - biospace.com/
SNYNF | News | $92.7 600K
|
Health Technology
|
| O: 1.6%
H: 0.0%
C: -6.5%
SNY | News | $46.34 2.09% 620K
|
Health Technology
|
| O: 0.4%
H: 0.84%
C: 0.37%
REGN | $894.35 0.04% 140K
|
Health Technology
|
| O: -0.41%
H: 3.27%
C: 1.6%
ALNY | News | $146.34 0.81% 64K
|
Health Technology
|
| O: -0.9%
H: 2.16%
C: 1.01%
ongoing report nash study phase 1
Innate Pharma Reports First Half 2022 Financial Results and Business Update
Published: 2022-09-15 (Crawled : 06:00) - biospace.com/
BNPQF | $68.558 400
|
Finance
|
| O: -1.65%
H: 0.0%
C: -2.85%
BNPQY | $34.61 100K
|
Finance and Insurance
|
| O: -1.12%
H: 2.34%
C: 1.69%
SNYNF | News | $92.7 600K
|
Health Technology
|
| O: 1.6%
H: 0.0%
C: -6.5%
NVO | $123.43 0.55% 1.4M
|
Health Technology
|
| O: -0.88%
H: 0.45%
C: -0.87%
SNY | News | $46.34 2.09% 620K
|
Health Technology
|
| O: 0.4%
H: 0.84%
C: 0.37%
IPHA | $2.35 2.3K
|
Health Technology
|
| O: 3.25%
H: 0.0%
C: 0.0%
pharma financial update results
Gainers vs Losers
| 79% | 21% |
Top 10 Gainers
AGBA | News | $1.22 205.0% 86M
|
Finance
EGOX | $0.0606 68.33% 250M
|
NVFY | $3.45 63.51% 20M
|
Consumer Durables
ZCMD | $1.98 36.55% 27M
|
Commercial Services
CHRO | $1.66 35.51% 70K
|
n/a
INDO | $5.43 33.09% 10M
|
Energy Minerals
PAPL | $2.07 26.22% 550K
|
RWOD | $10.08 26.05% 5.6M
|
n/a
AULT | $0.304 25.57% 47M
|
Manufacturing
HUSA 4 | $2.07 23.95% 2.1M
|
Energy Minerals
Your saved searches
Save your searches and get alerts when important news are released.